MMP-16 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human MMP-16 (MT3-MMP, UniProt P51512) expressed in HEK293 cells. Suited for substrate cleavage assays, progelatinase A activation studies, inhibitor screening, and antibody validation.
Expression system
HEK293
Cat. #
REC-MMP16

In stock

SKU
REC-MMP16
$498.00

Target Overview

MMP-16 (Matrix metalloproteinase-16, UniProt P51512) is a transmembrane-anchored member of the matrix metalloproteinase family, also designated MT3-MMP or MT-MMP 3. The full-length human protein spans 607 amino acids and localises to the cell membrane, where it functions as a zinc-dependent endopeptidase. This recombinant form is expressed in HEK293 cells, providing a mammalian glycosylation environment that supports correct folding of the catalytic domain and preserves native enzymatic activity — an important consideration for inhibitor binding studies where active-site geometry is critical. MMP-16 cleaves extracellular matrix substrates including fibronectin and collagen type III, but does not act on collagen types I, II, IV, or V under standard conditions. A well-characterised function is its activation of progelatinase A (pro-MMP-2) at the cell surface. The short isoform retains fibronectin and collagen III cleavage activity, though at a reduced rate relative to the full-length form. Upon interaction with CSPG4 (chondroitin sulfate proteoglycan 4), MMP-16 has been implicated in type I collagen degradation in the context of melanoma cell invasion. Researchers use this recombinant in direct substrate cleavage assays (fluorogenic peptide substrates or native fibronectin/collagen III preparations), in proMMP-2 activation cascade studies, and as a positive-control antigen for Western blot or IHC antibody validation. The HEK293 expression system minimises endotoxin interference and produces protein compatible with both biochemical and cell-based assay formats. Investigators screening small-molecule MMP-16 inhibitors — including hydroxamate and non-hydroxamate chemotypes — use this recombinant to establish IC50 values in fluorescence-based activity assays. For antibody validation applications, this recombinant pairs directly with the Triple Point Biologics matched antibody (SKU: RP-MMP16).

Background

MMP-16 belongs to the membrane-type (MT-MMP) sub-family of matrix metalloproteinases, a group defined by a C-terminal transmembrane domain that anchors enzymatic activity at the pericellular space rather than releasing it into bulk extracellular fluid. This spatial restriction makes MT-MMPs particularly relevant to cell invasion, matrix remodeling at cell-matrix contact zones, and the regulated activation of soluble MMP zymogens. MMP-16 specifically activates progelatinase A (pro-MMP-2) through a mechanism that requires cell-surface localisation, and this activation event has been studied in the context of vascular remodeling and tumour stroma. In cancer biology, MMP-16 expression has been characterised in several tumour types. A 2026 study by Yang T et al. (PMID 41507135) described an exosome-transmitted lncRNA (SNHG1) that drives prostate cancer bone metastasis partly through a YBX1/MMP16 regulatory axis, placing MMP-16 as a downstream effector in a transcriptionally governed invasion programme. This kind of mechanistic study — linking upstream RNA-based regulation to MMP-16 protein output — is precisely the context in which a well-characterised recombinant standard supports parallel biochemical validation of enzymatic activity changes. MMP-16 has also been studied for its collagenolytic activity in post-mortem tissue remodeling settings. Zhang TB et al. (PMID 41636238) demonstrated synergistic collagen degradation by MMP-3 and MMP-16 in abalone muscle, providing quantitative insights into how MMP family members cooperate to degrade fibrillar collagen substrates — work that has direct methodological parallels in mammalian ECM remodeling research. At the population genetics level, MMP-16 has appeared in proteome-wide Mendelian randomization analyses investigating causal protein-disease relationships (Lin J et al., PMID 41836659), and MMP family members more broadly have been assessed for causal relationships with conditions such as diabetic retinopathy (Qiu X et al., PMID 41578579). These genetic epidemiology findings position MMP-16 as a research target for studies examining protease-mediated tissue pathology. Skeletal muscle expression of MMP16 has additionally been identified in epigenomic and transcriptomic profiling of buffalo skeletal muscle (Zhao S et al., PMID 41751011), suggesting a conserved role for this protease in musculoskeletal extracellular matrix maintenance across species. Taken together, published work supports use of recombinant MMP-16 across a range of in vitro research paradigms — from substrate specificity mapping and inhibitor characterisation to use as an antigen standard for antibody-based detection methods. Triple Point Biologics has produced validated proteinase and inhibitor antibody reagents since 1994; this recombinant extends that portfolio into active protein tools for the same research community.

Applications

  • Fluorogenic peptide substrate cleavage activity assay (e.g., Mca-PLGL-Dpa-AR-NH2 or equivalent MMP consensus substrates)
  • Progelatinase A (pro-MMP-2) activation cascade assay in cell-free system
  • Small-molecule inhibitor IC50 determination by fluorescence-based enzymatic assay
  • Native substrate cleavage assay using fibronectin or collagen type III as substrate, analysed by SDS-PAGE or ELISA
  • Positive-control antigen for Western blot validation of anti-MMP-16 antibodies (pairs with TPB SKU: RP-MMP16)
  • Positive-control antigen for IHC antibody titration and specificity confirmation
  • Surface plasmon resonance (SPR) or biolayer interferometry (BLI) binding kinetics with candidate inhibitor compounds
  • Substrate identification and active-site mapping by mass spectrometry-based proteomics (TAILS or equivalent N-terminomics)

References

  1. Lin J et al. Proteome-wide Mendelian randomization and colocalization analyses identify potential biomarkers for schizophrenia. Front Psychiatry. 2026. doi:10.3389/fpsyt.2026.1724567. PMID: 41836659.
  2. Zhao S et al. Integrative Analysis of Whole-Genome Bisulfite Sequencing and RNA-Seq in Skeletal Muscle of Xin'anjiang Water Buffalo. Animals (Basel). 2026. doi:10.3390/ani16040549. PMID: 41751011.
  3. Zhang TB et al. Mechanistic Insights into Synergistic Collagen Degradation by MMP-3 and MMP-16 in Post-Mortem Abalone Muscle. J Agric Food Chem. 2026. doi:10.1021/acs.jafc.5c16557. PMID: 41636238.
  4. Qiu X et al. Causal relationship between matrix metalloproteinases and diabetic retinopathy: A bidirectional two-sample Mendelian randomization study. Medicine (Baltimore). 2026. doi:10.1097/MD.0000000000047363. PMID: 41578579.
  5. Yang T et al. Exosome-transmitted long noncoding RNA SNHG1 promotes prostate cancer bone metastasis via YBX1/MMP16 axis. Cell Death Discov. 2026. doi:10.1038/s41420-025-02855-5. PMID: 41507135.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl₂, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Secreted; Extracellular matrix

Frequently Asked Questions

What is the expected molecular weight of recombinant MMP-16 on SDS-PAGE or Western blot?

The full-length human MMP-16 (UniProt P51512) has a predicted MW of ~68 kDa from its 607-amino-acid sequence, but the recombinant form expressed in HEK293 cells typically migrates at approximately 70–75 kDa under reducing SDS-PAGE conditions, reflecting mammalian N-linked glycosylation. Under non-reducing conditions, migration may shift slightly depending on disulfide bond status. Purity is confirmed at >95% by SDS-PAGE. If you are running a Western blot positive control alongside our matched antibody RP-MMP16, expect a clean band in the 70–75 kDa range.

Does recombinant MMP-16 represent the full-length protein or a catalytic domain fragment?

This recombinant corresponds to the catalytic domain of MMP-16 rather than the full transmembrane-anchored 607-aa protein. The transmembrane anchor is omitted to enable soluble, active enzyme expression in HEK293 cells — a standard approach for MT-MMPs intended for in-solution biochemical assays. The catalytic domain retains the zinc-dependent endopeptidase activity characteristic of native MMP-16, including fibronectin and collagen type III cleavage, and supports pro-MMP-2 activation studies in cell-free systems. Researchers requiring the full-length membrane-localised context should use cell-based expression systems.

What substrates does recombinant MMP-16 cleave and which collagens should I avoid using in assays?

MMP-16 cleaves fibronectin and collagen type III with well-characterised efficiency and activates progelatinase A (pro-MMP-2) at the cell surface — both activities are retained by this recombinant catalytic domain. It does not cleave collagen types I, II, IV, or V under standard assay conditions, so these should not be used as positive substrate controls. For fluorescence-based activity assays, a broad-spectrum MMP FRET substrate such as Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 is appropriate for confirming lot activity before advancing to ECM substrate panels.

What assay buffer should I use for MMP-16 activity assays and does the storage buffer interfere?

MMP-16 is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, and 5 mM CaCl₂. For activity assays, dilute into a standard MMP assay buffer containing 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl₂, and 0.05% Brij-35 — the detergent reduces non-specific surface adsorption without inhibiting the zinc-active site. Keep CaCl₂ at ≥1 mM throughout; calcium depletion rapidly destabilises the catalytic domain. At final working dilutions (≥10-fold), residual glycerol from the storage buffer does not measurably affect fluorometric readouts.

What starting concentration of recombinant MMP-16 should I use for a fluorometric FRET activity assay?

A starting concentration of 50–200 nM recombinant MMP-16 in a 100 µL assay volume is a practical working range with a 10 µM FRET substrate (e.g., Mca-PLGL-Dpa-AR-NH₂). Run an enzyme titration at 25, 50, 100, and 200 nM to identify the linear range for your substrate and plate reader. Because lot-to-lot specific activity can vary within the >95% purity specification, confirming activity on receipt with a small pilot assay before committing samples to inhibitor IC₅₀ experiments is advisable. The 5 mM CaCl₂ in the storage buffer is compatible with direct dilution into most MMP assay buffers.

How do I account for MMP-16 glycosylation when running inhibitor binding or IC50 experiments?

Because this recombinant is expressed in HEK293 cells, the catalytic domain carries mammalian N-linked glycosylation, which supports the native active-site geometry relevant to inhibitor binding studies — a meaningful advantage over E. coli-derived or deglycosylated preparations where active-site conformation can be compromised. When calculating IC₅₀ values, confirm that the inhibitor concentration range brackets at least two orders of magnitude around the expected Ki, and hold enzyme concentration well below the Ki to avoid tight-binding artefacts. Substrate and enzyme concentrations should be validated in the linear range before advancing to inhibitor titrations.

Can I use recombinant MMP-16 as a Western blot positive control with the RP-MMP16 antibody?

Yes — REC-MMP16 is the intended positive control for RP-MMP16. Load 10–50 ng of recombinant protein per lane under reducing conditions; 20 ng is a reliable starting point for most chemiluminescence detection systems. Expect a band at ~70–75 kDa. RP-MMP16 is a rabbit polyclonal validated for Western blot at Triple Point Biologics, and both products were developed from the same research program, ensuring epitope–protein compatibility. This pairing is particularly useful for validating antibody performance against cell lysates where endogenous MMP-16 expression is low or variable.

How much recombinant MMP-16 should I load alongside RP-MMP16 antibody for antibody validation on Western blot?

For antibody validation experiments using RP-MMP16, loading a titration of 5, 20, and 50 ng of REC-MMP16 per lane is the most informative approach: it demonstrates both sensitivity (lowest detectable amount) and linearity of the antibody signal. Run alongside your cell lysate of interest so the recombinant band at ~70–75 kDa serves as an unambiguous size marker for the endogenous protein. This three-point titration typically requires less than 200 ng total recombinant protein, well within a single aliquot, and provides publication-quality documentation of antibody specificity.

How should I store recombinant MMP-16 and what is the recommended shelf life after aliquot thaw?

Store REC-MMP16 at -20°C in the supplied single-use aliquots. The 10% glycerol in the storage buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl₂) acts as a cryoprotectant and ensures protein stability through multiple freeze-thaw cycles is not necessary — aliquots are sized to avoid this entirely. Once thawed, keep on ice and use within 24 hours; do not refreeze. Residual activity after extended incubation at 4°C degrades measurably beyond 48 hours. Under recommended conditions, shelf life from manufacture is 12 months.

Validation imagery coming soon

Western blot validation figures for REC-MMP16 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →